Biotherapies in Uveitis
Non-infectious uveitis (NIU) represents one of the leading causes of blindness in developed countries. The therapeutic strategy aims to rapidly control intra-ocular inflammation, prevent irremediable ocular damage, allow corticosteroid sparing and save the vision, and has evolved over the last few y...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/11/3599 |
id |
doaj-16aa24989dfb466dad2babf6dc81e85f |
---|---|
record_format |
Article |
spelling |
doaj-16aa24989dfb466dad2babf6dc81e85f2020-11-25T04:09:40ZengMDPI AGJournal of Clinical Medicine2077-03832020-11-0193599359910.3390/jcm9113599Biotherapies in UveitisMathilde Leclercq0Anne-Claire Desbois1Fanny Domont2Georgina Maalouf3Sara Touhami4Patrice Cacoub5Bahram Bodaghi6David Saadoun7Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, FranceDepartment of Internal Medicine and Clinical Immunology, AP-HP, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, FranceDepartment of Internal Medicine and Clinical Immunology, AP-HP, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, FranceDepartment of Internal Medicine and Clinical Immunology, AP-HP, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, FranceDepartment of Ophthalmology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, FranceDepartment of Internal Medicine and Clinical Immunology, AP-HP, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, FranceDepartment of Ophthalmology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, FranceDepartment of Internal Medicine and Clinical Immunology, AP-HP, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, FranceNon-infectious uveitis (NIU) represents one of the leading causes of blindness in developed countries. The therapeutic strategy aims to rapidly control intra-ocular inflammation, prevent irremediable ocular damage, allow corticosteroid sparing and save the vision, and has evolved over the last few years. Anterior NIU is mostly managed with topical treatment in adults. However, for intermediate, posterior and pan-uveitis, notably when both eyes are involved, systemic treatment is usually warranted. Biotherapies are recommended in case of inefficacy or non-tolerance of conventional immunosuppressive drugs in non-anterior NIU. Anti-tumor necrosis factor alpha (anti-TNF-α) agents are by far the most widely used, especially adalimumab (ADA) and infliximab (IFX). In case of sight-threatening uveitis in Behçet’s disease or in case of risk of severe recurrences, respectively IFX and ADA may be recommended as first-line therapy. Many questions are left unanswered; how long to treat NIU, how to discontinue anti-TNF-α agents, what biologic to use in case of anti-TNF-α failure? The objective of this review is to present an updated overview of knowledge on the use of biological treatments in NIU.https://www.mdpi.com/2077-0383/9/11/3599non-infectious uveitisbiotherapyanti-TNF-α (anti-tumor necrosis factor alpha) agenttocilizumabJanus Associated Kinase (JAK) inhibitors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mathilde Leclercq Anne-Claire Desbois Fanny Domont Georgina Maalouf Sara Touhami Patrice Cacoub Bahram Bodaghi David Saadoun |
spellingShingle |
Mathilde Leclercq Anne-Claire Desbois Fanny Domont Georgina Maalouf Sara Touhami Patrice Cacoub Bahram Bodaghi David Saadoun Biotherapies in Uveitis Journal of Clinical Medicine non-infectious uveitis biotherapy anti-TNF-α (anti-tumor necrosis factor alpha) agent tocilizumab Janus Associated Kinase (JAK) inhibitors |
author_facet |
Mathilde Leclercq Anne-Claire Desbois Fanny Domont Georgina Maalouf Sara Touhami Patrice Cacoub Bahram Bodaghi David Saadoun |
author_sort |
Mathilde Leclercq |
title |
Biotherapies in Uveitis |
title_short |
Biotherapies in Uveitis |
title_full |
Biotherapies in Uveitis |
title_fullStr |
Biotherapies in Uveitis |
title_full_unstemmed |
Biotherapies in Uveitis |
title_sort |
biotherapies in uveitis |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2020-11-01 |
description |
Non-infectious uveitis (NIU) represents one of the leading causes of blindness in developed countries. The therapeutic strategy aims to rapidly control intra-ocular inflammation, prevent irremediable ocular damage, allow corticosteroid sparing and save the vision, and has evolved over the last few years. Anterior NIU is mostly managed with topical treatment in adults. However, for intermediate, posterior and pan-uveitis, notably when both eyes are involved, systemic treatment is usually warranted. Biotherapies are recommended in case of inefficacy or non-tolerance of conventional immunosuppressive drugs in non-anterior NIU. Anti-tumor necrosis factor alpha (anti-TNF-α) agents are by far the most widely used, especially adalimumab (ADA) and infliximab (IFX). In case of sight-threatening uveitis in Behçet’s disease or in case of risk of severe recurrences, respectively IFX and ADA may be recommended as first-line therapy. Many questions are left unanswered; how long to treat NIU, how to discontinue anti-TNF-α agents, what biologic to use in case of anti-TNF-α failure? The objective of this review is to present an updated overview of knowledge on the use of biological treatments in NIU. |
topic |
non-infectious uveitis biotherapy anti-TNF-α (anti-tumor necrosis factor alpha) agent tocilizumab Janus Associated Kinase (JAK) inhibitors |
url |
https://www.mdpi.com/2077-0383/9/11/3599 |
work_keys_str_mv |
AT mathildeleclercq biotherapiesinuveitis AT anneclairedesbois biotherapiesinuveitis AT fannydomont biotherapiesinuveitis AT georginamaalouf biotherapiesinuveitis AT saratouhami biotherapiesinuveitis AT patricecacoub biotherapiesinuveitis AT bahrambodaghi biotherapiesinuveitis AT davidsaadoun biotherapiesinuveitis |
_version_ |
1724422234482671616 |